Salute e Benessere

Oxurion announces it obtained an improved indicative EUR 30 million financing…

Leuven, Belgium, August 4, 2025 – 06:00 PM CEST – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces that it has received an improved indicative financing offer from Atlas Special Opportunities for a total amount of €30 million. The proposed financing would be structured in 10 successive tranches of €3m…
Actusnews Wire
04/08/2025

Oxurion kondigt aan dat het een verbeterd indicatief financieringsaanbod van EUR…

Leuven, BELGIË, 4 augustus 2025 – 18u00 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, kondigt aan dat het een verbeterd indicatief financieringsaanbod heeft ontvangen van Atlas Special Opportunities, voor een totaalbedrag van €30 miljoen. De voorgestelde financiering zou gestructureerd…
Actusnews Wire
04/08/2025

CROSSJECT remains engaged during the summer break

Press ReleaseCROSSJECT remains engaged during the summer breakMaintenance operations are being carried out at production sites.Regulatory and development activities are continuing actively.Dijon, France, August 4, 2025 (5:30 p.m. CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceutical company developing emergency products based on its proprietary ZENEO® needle-free auto-injector technology, remains fully engaged to submitting the ZEPIZURE® dossier...
Nasdaq GlobeNewswire
04/08/2025

Medical Device Contract Manufacturing Market to Grow at a CAGR of 11.4% from…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/medical-device-contract-manufacturing-market Get a Free Sample Report -https://www.skyquestt.com/sample-request/medical-device-contract-manufacturing-market Medical Device Contract Manufacturing Key Growth Drivers Increasing popularity of outsourcing medical device manufacturing to focus on core competencies like R&D and marketing is driving market growth. Contract manufacturers offer scalable operations,...
PR Newswire
04/08/2025

MAXIMA GRUPĖ, UAB Maintains BB+ Credit Rating with Stable Outlook from S&P…

On July 31, 2025, the international credit rating agency S&P Global Ratings conducted its annual review of the group’s operations and financial results. Following the review, MAXIMA GRUPĖ’s credit rating remained unchanged. The S&P Global Ratings report highlights the group’s growing revenues despite high competition, strong private label positioning, expansion of managed retail chains, and good diversification of store formats. According to S&P Global Ratings’ methodology,...
Nasdaq GlobeNewswire
04/08/2025

Cell Culture Market is expected to generate a revenue of USD 93.49 Billion by…

The Cell Culture Market is witnessing robust growth as it plays a critical role in drug development, vaccine production, and stem cell research. Increasing R&D activities and the rising demand for monoclonal antibodies are contributing significantly to market expansion. The Cell Culture Market is witnessing robust growth as it plays a critical role in drug development, vaccine production, and stem cell research. Increasing R&D activities and the rising demand for monoclonal antibodies…
PR Newswire
04/08/2025

Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered…

"For too long, women have suffered from health conditions that are misunderstood, misdiagnosed, or ignored," said Dr. Anita Zaidi, president of the Gates Foundation's Gender Equality Division. "We want this investment to spark a new era of women-centered innovation—one where women's lives, bodies, and voices are prioritized in health R&D." "For too long, women have suffered from health conditions that are misunderstood, misdiagnosed, or ignored," said Dr.Anita…
PR Newswire
04/08/2025

Pulsecare Medical Announces NMPA Approval of NxPFA™, the World's First…

PFA has revolutionized AF treatment through its tissue selectivity, safety, and procedural efficiency. Yet, early-generation systems using microsecond pulses face key challenges—excessive muscle stimulation, reliance on general anesthesia, and risks like hemolysis and gas embolism—that limit broad adoption. PFA has revolutionized AF treatment through its tissue selectivity, safety, and procedural efficiency. Yet, early-generation systems using microsecond pulses face key challenges—excessive...
PR Newswire
04/08/2025

Orion Corporation: Managers’ transactions – Satu Ahomäki

ORION CORPORATIONMANAGERS’ TRANSACTIONS4 August 2025 at 16:10 EEST Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
04/08/2025

MosaiQ AiPlex® Vasculitis assay now available for clinical use in the European…

The MosaiQ AiPlex VAS assay is designed to improve time to results to support diagnosis of autoimmune vasculitis, while simplifying laboratory workflows. ANCA-associated vasculitides comprise three distinct syndromes - granulomatosis with polyangiitis (GPA, formerly known as Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome). If left untreated, Anti-GBM disease can lead to life-threatening…
PR Newswire
04/08/2025

Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support…

The site includes: The site includes: "The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally," saidDr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. "It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability." "This facility embodies our shared vision for the future of cell…
PR Newswire
04/08/2025

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic…

Click here to view the custom infographic of the Soligenix Inc. editorial. Clickhere to view the custom infographic of the Soligenix Inc. editorial. Chronic rare diseases are emerging as a major challenge within the aging U.S. population. As life expectancy increases, so too does the complexity of healthcare needs, particularly when it comes to conditions that are both long-lasting and difficult to diagnose. Tens of millions of Americans are facing life with a rare disease, and many of...
PR Newswire
04/08/2025

Accumulus Synergy Spins Out Accumulus Technologies to Scale Proven Regulatory…

The spinout includes both the transfer of the Accumulus platform and the team responsible for its development, representing a strategic step toward broader Platform adoption and deeper support for the life sciences - regulatory ecosystem. Accumulus Technologies will lead the ongoing advancement of the Platform to meet growing global demand.“The Accumulus platform has reached a critical point in its trajectory, and the opportunity to expand its impact and reach has never been greater,” said...
Nasdaq GlobeNewswire
04/08/2025

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L11 and VEGF-A Entered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb (“BMS”) to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types...
Nasdaq GlobeNewswire
04/08/2025

HKBU leads the development of multifunctional nanorobots for precise and…

Professor Ken Leung Cham-fai, Associate Professor of the Department of Chemistry at HKBU, in collaboration with scientists from the University of Science and Technology of China, Hefei University of Technology, and the Dongcheng branch of the First Affiliated Hospital of Anhui Medical University, have designed and fabricated a nanorobot, which demonstrates capabilities in breaking down organic pollutants, exhibits antibacterial properties, and removes biofilms. The research findings have been…
PR Newswire
04/08/2025

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance…

Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner. This partnership propels Alveolus Bio's live biotherapeutics and small molecule platform towards Phase 2 and first-in-human clinical trials, with a lead asset for COPD progressing rapidly. Through this collaboration,Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development...
PR Newswire
04/08/2025

New Way to Take Iron: IBSA Launches Innovative Orally Dissolving Film Supplement…

At a time when up to a third of UK adults report difficulty swallowing pills¹, and many struggle with the gastrointestinal side effects of traditional iron supplements², IBSA Iron ODF offers a welcome solution. Using IBSA’s patented FilmTec ®technology, this small, lemon-flavoured strip melts in the mouth quickly, delivering a precise dose of 30 mg iron (as ferric pyrophosphate) and 400 μg folic acid with minimal digestive discomfort. “I’ve been taking Iron supplements for over 10 years...
Nasdaq GlobeNewswire
04/08/2025

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet…

ABT-301 is an oral HDAC1/2/3 inhibitor. Preclinical studies have shown that it promotes CD8+ cytotoxic T cell infiltration and activity, enhances antigen presentation, and inhibits M-MDSCs cells, effectively modulating the tumor microenvironment and converting "cold tumors" into "hot tumors" to improve the efficacy of immune checkpoint inhibitors. ABT-301 also exhibits pro-apoptotic, anti-angiogenic, and tumor metabolic regulation effects. As a single-molecule…
PR Newswire
04/08/2025

Oxurion rondt overname van Axiodis CRO af en versnelt uitbouw van haar Europese…

Oxurion kondigt de volledige afronding aan van de overname van 72% van het aandelenkapitaal van Axiodis CRO. Deze overnamne vormt de eerste stap in de uitbouw van een geïntegreerd platform rond klinische data. De Groep versnelt de gesprekken met aanvullende strategische partners in Frankrijk en de rest Europa…
Actusnews Wire
04/08/2025

Casino Group: Repayments confirmation to Quatrim secured bondholders

Repayments confirmation to Quatrim secured bondholders Paris, August 4, 2025Groupe Casino announces that it has repaid €23.5m of the secured debt carried by its subsidiary Quatrim, of which €3.5m on June 25 and €20.0m on August 1. These repayments include €23.0m of principal and €0.5m of accrued interests.Following these transactions, the nominal amount of the Quatrim secured bonds is €198 m. ***This communication is for informational purposes only under the current applicable...
Nasdaq GlobeNewswire
04/08/2025

Oxurion completes the acquisition of Axiodis CRO and accelerates the structuring…

Oxurion announces the full completion of the acquisition of a 72% equity stake in Axiodis CRO This transaction marks the first step in building an integrated platform focused on clinical data The Group is intensifying discussions with additional strategic targets in France and across Europe Leuven, Belgium, August 4, 2025 – 08:30 CEST – Oxurion NV…
Actusnews Wire
04/08/2025

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive…

With this qualification in place, sponsors can now use the Simcyp Simulator in regulatory submissions across the EU to assess drug-drug interaction (DDI) risk without needing to re-establish the platform’s credibility for the specified context of use (COU) scenarios. Simcyp has long been the leading biosimulation software used in submissions to the EU and other regulatory agencies, and this qualification makes the drug submission process easier and faster. “This first of its kind...
Nasdaq GlobeNewswire
04/08/2025

Pharming Group to participate in August investor conference

Leiden, the Netherlands, August 4, 2025:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of August:Canaccord Genuity 45 thAnnual Growth Conference, Boston, USA, August 12-13, 2025Fabrice Chouraqui, Chief Executive Officer, will present on Tuesday, August 12 at 12:00pm EDT/18:00 CEST.For more information about this conference, or to schedule a...
Nasdaq GlobeNewswire
04/08/2025

EssilorLuxottica: EssilorLuxottica acquires Automation & Robotics, advancing…

EssilorLuxottica acquires Automation & Robotics, advancing high-performance solutions in ophthalmic manufacturingParis, France (4 August 2025)– EssilorLuxottica announces today the acquisition of Automation & Robotics (A&R), a renowned player in the design and manufacture of automated systems for optical lens quality control, serving both mass production facilities and prescription laboratories. Headquartered in Belgium and operating since 1983, A&R has built a...
Nasdaq GlobeNewswire
04/08/2025
Altri  Comunicati